TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04323683

Intervention type: GENETIC
Intervention: Microarray
Description: High throughput technique for determining global gene expression of the condition of interest

Intervention type: GENETIC
Intervention: Microarray
Description: High throughput technique for determining global gene expression of the condition of interest
Study: NCT00469885

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine replacement
Description: For reduction

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivational counseling
Description: No drugs
Study: NCT03531645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Neoadjuvant Treatment (Cycles 1-4): Fulvestrant 500 mg injection in buttocks on Days 1 and 15 of Cycle 1 and Day 1 of Cycles 2-4.~Adjuvant Treatment (Cycles 5 and beyond): Fulvestrant 500 mg injection in buttocks on Day 1 of each cycle.~Study cycle is 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Neoadjuvant Treatment (Cycles 1-4): Abemaciclib 150 mg by mouth On Days 1-28 of each cycle.~Adjuvant Treatment (Cycles 5 and beyond): On Days 1-28 of each cycle, you will take Abemaciclib 150 mg by mouth on Days 1-28 of each cycle.~Study cycle is 28 days.
Study: NCT04007796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Apnea and Insomnia Relief (AIR)
Description: This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education (SE)
Description: This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
Study: NCT00974350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SABER-Bupivacaine
Description: Injectable Extended Release Solution; 2.5 mL SABER-Bupivacaine/Once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SABER-Bupivacaine
Description: Injectable Extended Release Solution; 5.0 mL SABER-Bupivacaine/Once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SABER-Placebo
Description: Injectable Solution; 2.5 or 5.0 mL SABER-Placebo/Once
Study: NCT03616691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Stage I: The dose level of atezolizumab proposed to be tested in this study is 1200 mg administered by IV infusion every 3 weeks (q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Stage I: The dose level of atezolizumab proposed to be tested in this study is 1200 mg administered by IV infusion every 3 weeks (q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Stage II: Once radiologic progression confirmed from atezolizumab monotherapy (stage 1), 1200mg of atezolizumab would be administered with 15mg/kg of bevacizumab as combination therapy every 3 weeks.
Study: NCT03008655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intradermal tranexamic acid
Description: intradermal tranexamic acid injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nd-YAG
Description: six session at two-week interval of low influence 1064 Nd:YAG laser (6 mm spot size, energy fluence 1.2 - 1.4 J/cm 2 at 10 Hz)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd-YAG
Description: six session at two-week interval of low influence 1064 Nd:YAG laser (6 mm spot size, energy fluence 1.2 - 1.4 J/cm 2 at 10 Hz)
Study: NCT06098313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: -Cyclophosphamide 50 mg/kg/day i.v. daily on days 3 and 4 (for 2 days)
Study: NCT00863330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Tumor harvest process tumor infiltrating lymphocytes. Non myeloblative chemotherapy consisting of cyclophosphamide and fludarabine. Infusion of TIL cells followed by high dose IL-2.
Study: NCT01215760

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training with a mirror
Description: Early sensory reeducation group, started at the first week postoperatively, using specific guidelines using the mirror training and stimulation of the contralateral side. Initially, the stimulation will be unilateral and later bilateral, after the removal of the splint in 4 weeks.
Study: NCT00731432

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Identical in shape and texture to treatment patch
Study: NCT03673410

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic bariatric surgery - revisional
Description: Using robotic techniques during any revesional bariatric surgery
Study: NCT01215760

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No mirror therapy
Description: The classical group iniciates after 16 weeks postoperatively and follow a standard home protocol for sensory reeducation without the mirror. It begins with recognition of textures and objects, and specific rehabilitation, if any associated injuries.
Study: NCT00232687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets, Oral, 15 mg fixed dose (week 1-5) flexible dose 10-30 mg (week 6-12), once daily, 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets, Oral, Uptitration: 5 mg (week 1), 10 mg (week 2 and 3), 15 mg(week 4 and 5) flexible 10-30mg from week 6-12, once daily, 12 weeks.
Study: NCT01360086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 6 cycles of intravenous Cetuximab (500mg/m²),

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatine (50mg/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Surgery was planned 3-4 weeks after the end of neaodjuvant CT
Study: NCT04598763

Intervention type: OTHER
Group type: OTHER
Intervention: smell the odors of the olfactory rehabilitation kit according to the classic or intensive method
Description: regardless of the randomization group, the patient will smell each odor for 10 seconds with a 10 second interval between odors.

Intervention type: OTHER
Group type: OTHER
Intervention: smell the odors of the olfactory rehabilitation kit according to the classic or intensive method
Description: regardless of the randomization group, the patient will smell each odor for 10 seconds with a 10 second interval between odors.
Study: NCT06416241

Intervention type: DRUG
Group type: OTHER
Intervention: EYLEA 2 MG in 0.05 ML Injection
Description: Intravitreal injection
Study: NCT00767481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost/Brinzolamide
Description: Eye drop suspension, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost/Brinzolamide
Description: Eye drop suspension, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosopt
Description: Eye drop solution, one drop BID
Study: NCT04366635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Impacted third molar surgery
Description: Under local anesthesia, flap will be raised and mesioangular or horizontal impacted third molar tooth will be removed with routine technique. And then extraction socket will be irrigated with salin and will be primarily closed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Impacted third molar surgery
Description: Under local anesthesia, flap will be raised and mesioangular or horizontal impacted third molar tooth will be removed with routine technique. And then extraction socket will be irrigated with salin and will be primarily closed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Impacted third molar surgery
Description: Under local anesthesia, flap will be raised and mesioangular or horizontal impacted third molar tooth will be removed with routine technique. And then extraction socket will be irrigated with salin and will be primarily closed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of mineralised plasmatic matrix
Description: After extraction of impacted third molar tooth, Mineralized Plasmatic Matrix will be placed to the socket as a graft material and will be covered with Platelet Rich Fibrin membrane. Then wound will be primarily closed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of β-tricalcium phosphate
Description: After extraction of impacted third molar tooth, β-tricalcium phosphate will be placed to the socket as a graft material and will be covered with Platelet Rich Fibrin membrane. Then wound will be primarily closed.
Study: NCT02950974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterofundin
Description: Fluid loading

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterofundin
Description: Fluid loading

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSS
Description: Fluid loading

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSS
Description: Fluid loading
Study: NCT03608007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-396 Capsule
Description: 225 mg once daily
Study: NCT00866775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: 1600 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: 1200 mg QD
Study: NCT00714363

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK
Description: Refractive surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SBK
Description: Refractive surgery
Study: NCT03673410

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic bariatric surgery - revisional
Description: Using laparoscopic techniques during any revesional bariatric surgery
Study: NCT01887301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex
Description: Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex
Description: Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex
Description: Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.
Study: NCT03878186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care (UC)
Description: Usual Care: single in-person psycho-educative session with information about HIV, transmission, natural history of the disease, importance of antiretroviral adherence. All the information is based on guidelines and information sheets from InfoVIHt

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care (UC)
Description: Usual Care: single in-person psycho-educative session with information about HIV, transmission, natural history of the disease, importance of antiretroviral adherence. All the information is based on guidelines and information sheets from InfoVIHt

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Cognitive behavioral therapy (CBT): Usual Care + Cognitive-behavioral therapy program intervention (AppraHIV). This intervention involves 7 in-person weekly sessions based on Adjuvant Psychological Therapy centered in three areas: cognitive appraisal, affect and adherence and self-care, everyone with different techniques: cognitive techniques, diaphragmatic breathing, scheduling pleasurable activities, use of pillbox, solving problems, planning for the future, etc. The intervention was manualized (according to Template for Intervention Description and Replication TIDieR), piloted and validated.
Study: NCT02577835

Intervention type: DEVICE
Intervention: Ambulatory blood pressure monitoring
Description: Ambulatory blood pressure monitoring with arterial stiffness evaluation at 6-12 month intervals.
Study: NCT03483818

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment & Treatment of HCV infection with oral antivirals
Description: This is a cluster randomised trial of directly observed anti HCV therapy versus conventional care in HCV positive patients, who are in a pharmacist delivered OST program, where the patients attending an individual pharmacist are the cluster. Pharmacies participating in the trial will be allocated to conventional care pathway or the pharmacist-led pathway.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment & Treatment of HCV infection with oral antivirals
Description: This is a cluster randomised trial of directly observed anti HCV therapy versus conventional care in HCV positive patients, who are in a pharmacist delivered OST program, where the patients attending an individual pharmacist are the cluster. Pharmacies participating in the trial will be allocated to conventional care pathway or the pharmacist-led pathway.
Study: NCT03210038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Pad soaked with lidocaine gel (Esracaine) left on the introitus for 5 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Pad soaked with lidocaine gel (Esracaine) left on the introitus for 5 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Water based non-anesthetic lubricant gel left on the introitus for 5 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Water based non-anesthetic lubricant gel left on the introitus for 5 minutes.
Study: NCT01793584

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic hysterectomy
Description: LAVH, TLH

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal hysterectomy
Description: TAH
Study: NCT00072514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV in CD20-POSITIVE LYMPHOMAS cases
Study: NCT00470379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: resiquimod
Description: Escalating the dose of resiquimod applied to a fixed area of skin followed by application of topical NY-ESO-1b.
Study: NCT03574805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRS-060
Description: Study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalant designed to mimic PRS-060
Study: NCT01239303

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Citrulline
Description: single dose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: alanine
Description: single dose
Study: NCT04524429

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Bariatric surgery includes sleeve gastrectomy and gastric bypass.
Study: NCT01594814

Intervention type: PROCEDURE
Intervention: RFA
Description: radiofrequency ablation of slow pathway or accesory pathway
Study: NCT02773537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve catheter and sciatic nerve block
Description: This nerve block is believed to cause both muscle weakness and numbness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes both the front and the back of the knee to be numb.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal catheter and selective tibial block
Description: This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it to control pain. This technique causes both the front and the back of the knee to be numb.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal catheter only
Description: This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes only the front of the knee to be numb
Study: NCT01840163

Intervention type: OTHER
Group type: OTHER
Intervention: Static version of CanSORT tool

Intervention type: OTHER
Group type: OTHER
Intervention: CanSORT Online Tool
Study: NCT03607669

Intervention type: OTHER
Intervention: Mangafodipir trisodium
Description: Manganese-based MRI contrast agent

Intervention type: OTHER
Intervention: Mangafodipir trisodium
Description: Manganese-based MRI contrast agent
Study: NCT03678363

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tai chi chuan
Description: Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breating, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai chi chuan
Description: Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breating, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
Study: NCT01093560

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fat feeding
Description: Each feeding will consist of 473 mL of nonfat milk and 50 gms oil. The oil will be high in saturated fat, monounsaturated fat or polyunsaturated fat.
Study: NCT00680498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mg
Study: NCT05531344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Composite Steep-pulse Treatment Device
Description: Applying the Composite Steep-pulse Treatment Device to treat the patients with Benign Prostatic Hyperplasia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin Hydrochloride Capsules
Description: Applying Tamsulosin Hydrochloride Capsules to treat the patients with Benign Prostatic Hyperplasia
Study: NCT02018510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 mg/kg, single dose IV administration of 3BNC117
Description: 1 mg/kg, single dose IV administration of 3BNC117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 mg/kg, single dose IV administration of 3BNC117
Description: 1 mg/kg, single dose IV administration of 3BNC117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 mg/kg, single dose IV administration of 3BNC117
Description: 3 mg/kg, single dose IV administration of 3BNC117
Study: NCT01633112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fingolimod
Description: capsule
Study: NCT00680498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab plus Photodynamic therapy
Description: Ranibizumab 0.5mg, combined with photodynamic therapy with Verteporfin (dosage per label)
Study: NCT03293511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin
Description: 24 IU of oxytocin nasal spray will be applied to each subject.
Study: NCT01632423

Intervention type: DRUG
Intervention: bimatoprost 0.01%
Description: Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
Study: NCT03744559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval Extinction Training (RET)
Description: Retrieval extinction training (RET) is a behavioral intervention that involves cue-elicited retrieval followed by extinction training (i.e., massed unreinforced exposure to drug-associated cues). The first element of RET involves briefly presenting drug-associated cues to retrieve drug use memories. The second element, occurring after a brief interval, involves extinction training. It is argued that the initial retrieval of the memories prior to extinction training initiates a period of instability, which is followed by reconsolidation of the memories back into long-term storage. Extinction training during the period of instability is presumed to overwrite the original drug-associated cue with a non-drug-associated cue, to attenuate expression of drug-seeking behavior.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Retrieval Extinction Training (RET)
Description: The control retrieval extinction training (RET) for the NR-E arms serves as the control intervention to the RET behavioral intervention. The first element of the control RET involves briefly presenting retrieval cues that contain neutral, non-smoking content. The second element, occurring after a brief interval, involves extinction training. Based on findings from the previous NIDA-funded R21, the R-E arm reported a significant 25 percent reduction in cigarettes smoked per day during the follow-up period versus the control NR-E arm.
Study: NCT04404907

Intervention type: OTHER
Intervention: no intervention
Description: This is a secondary analysis of registry data.

Intervention type: OTHER
Intervention: no intervention
Description: This is a secondary analysis of registry data.
Study: NCT03293511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin
Description: 24 IU of oxytocin nasal spray will be applied to each subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal placebo
Description: 24 IU of of placebo nasal spray will be applied to each subject.
Study: NCT01633112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate
Description: subcutaneous injection